Medicenna Therapeutics (MDNA) Stock Overview
A clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
MDNA Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Medicenna Therapeutics Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.66 |
| 52 Week High | CA$1.97 |
| 52 Week Low | CA$0.65 |
| Beta | 1.79 |
| 1 Month Change | -26.67% |
| 3 Month Change | -29.79% |
| 1 Year Change | -33.33% |
| 3 Year Change | -12.00% |
| 5 Year Change | -86.67% |
| Change since IPO | -75.56% |
Recent News & Updates
Recent updates
We Think Medicenna Therapeutics (TSE:MDNA) Needs To Drive Business Growth Carefully
Oct 18
Medicenna Therapeutics (TSE:MDNA) Is In A Good Position To Deliver On Growth Plans
Jun 14Companies Like Medicenna Therapeutics (TSE:MDNA) Are In A Position To Invest In Growth
Feb 28Here's Why We're Not Too Worried About Medicenna Therapeutics' (TSE:MDNA) Cash Burn Situation
Nov 08Is Medicenna Therapeutics (TSE:MDNA) In A Good Position To Deliver On Growth Plans?
Mar 01We're Hopeful That Medicenna Therapeutics (TSE:MDNA) Will Use Its Cash Wisely
Aug 07Will Medicenna Therapeutics (TSE:MDNA) Spend Its Cash Wisely?
Apr 14We're Hopeful That Medicenna Therapeutics (TSE:MDNA) Will Use Its Cash Wisely
Dec 30
Shareholder Returns
| MDNA | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | -13.2% | -5.2% | -2.7% |
| 1Y | -33.3% | 2.7% | 26.0% |
Return vs Industry: MDNA underperformed the Canadian Biotechs industry which returned 0.4% over the past year.
Return vs Market: MDNA underperformed the Canadian Market which returned 25.6% over the past year.
Price Volatility
| MDNA volatility | |
|---|---|
| MDNA Average Weekly Movement | 7.8% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 10.9% |
| 10% most volatile stocks in CA Market | 19.2% |
| 10% least volatile stocks in CA Market | 3.8% |
Stable Share Price: MDNA has not had significant price volatility in the past 3 months compared to the Canadian market.
Volatility Over Time: MDNA's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 18 | Fahar Merchant | www.medicenna.com |
Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It develops bizaxofusp, an interleukin- 4 (IL-4) targeted therapy for the treatment of recurrent glioblastoma. The company also develops MDNA11, a long-acting interleukin-2 (IL-2) to activate anti-cancer immune cells over immunosuppressive Tregs; MDNA209, an IL-2/IL-15 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host diseases; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; MDNA113, a tumor-targeting and activatable masked anti-PD-1-IL-2 BiSKITTM for cancer; and MDNA132, an IL-13 Superkine for various tumors.
Medicenna Therapeutics Corp. Fundamentals Summary
| MDNA fundamental statistics | |
|---|---|
| Market cap | CA$54.22m |
| Earnings (TTM) | -CA$12.99m |
| Revenue (TTM) | n/a |
Is MDNA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MDNA income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$12.99m |
| Earnings | -CA$12.99m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.16 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did MDNA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/24 15:33 |
| End of Day Share Price | 2026/03/24 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Medicenna Therapeutics Corp. is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Charles Zhu | Guggenheim Securities, LLC |
| Swayampakula Ramakanth | H.C. Wainwright & Co. |
| Dev Prasad | Lucid Capital Markets |